Tushar A Shah1,2,3,4, Haree K Pallera1, Cortney L Kaszowski3, William Thomas Bass1,3,4, Frank A Lattanzio5. 1. Department of Pediatrics, Eastern Virginia Medical School, Norfolk, VA, United States. 2. Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, United States. 3. Children's Specialty Group, Norfolk, VA, United States. 4. Children's Hospital of The King's Daughters, Norfolk, VA, United States. 5. Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA, United States.
Abstract
OBJECTIVE: Complement activation is instrumental in the pathogenesis of Hypoxic-ischemic encephalopathy (HIE), a significant cause of neonatal mortality and disability worldwide. Therapeutic hypothermia (HT), the only available treatment for HIE, only modestly improves outcomes. Complement modulation as a therapeutic adjunct to HT has been considered, but is challenging due to the wide-ranging role of the complement system in neuroinflammation, homeostasis and neurogenesis in the developing brain. We sought to identify potential therapeutic targets by measuring the impact of treatment with HT on complement effector expression in neurons and glia in neonatal HIE, with particular emphasis on the interactions between microglia and C1q. METHODS: The Vannucci model was used to induce HIE in term-equivalent rat pups. At P10-12, pups were randomly assigned to three different treatment groups: Sham (control), normothermia (NT), and hypothermia (HT) treatment. Local and systemic complement expression and neuronal apoptosis were measured by ELISA, TUNEL and immunofluorescence labeling, and differences compared between groups. RESULTS: Treatment with HT is associated with decreased systemic and microglial expression of C1q, decreased systemic C5a levels, and decreased microglial and neuronal deposition of C3 and C9. The effect of HT on cytokines was variable with decreased expression of pro and anti-inflammatory effectors. HT treatment was associated with decreased C1q binding on cells undergoing apoptosis. CONCLUSION: Our data demonstrate the extreme complexity of the immune response in neonatal HIE. We propose modulation of downstream effectors C3a and C5a as a therapeutic adjunct to HT to enhance neuroprotection in the developing brain.
OBJECTIVE: Complement activation is instrumental in the pathogenesis of Hypoxic-ischemic encephalopathy (HIE), a significant cause of neonatal mortality and disability worldwide. Therapeutic hypothermia (HT), the only available treatment for HIE, only modestly improves outcomes. Complement modulation as a therapeutic adjunct to HT has been considered, but is challenging due to the wide-ranging role of the complement system in neuroinflammation, homeostasis and neurogenesis in the developing brain. We sought to identify potential therapeutic targets by measuring the impact of treatment with HT on complement effector expression in neurons and glia in neonatal HIE, with particular emphasis on the interactions between microglia and C1q. METHODS: The Vannucci model was used to induce HIE in term-equivalent rat pups. At P10-12, pups were randomly assigned to three different treatment groups: Sham (control), normothermia (NT), and hypothermia (HT) treatment. Local and systemic complement expression and neuronal apoptosis were measured by ELISA, TUNEL and immunofluorescence labeling, and differences compared between groups. RESULTS: Treatment with HT is associated with decreased systemic and microglial expression of C1q, decreased systemic C5a levels, and decreased microglial and neuronal deposition of C3 and C9. The effect of HT on cytokines was variable with decreased expression of pro and anti-inflammatory effectors. HT treatment was associated with decreased C1q binding on cells undergoing apoptosis. CONCLUSION: Our data demonstrate the extreme complexity of the immune response in neonatal HIE. We propose modulation of downstream effectors C3a and C5a as a therapeutic adjunct to HT to enhance neuroprotection in the developing brain.
Authors: Serafina Perrone; Michael D Weiss; Fabrizio Proietti; Candace Rossignol; Sara Cornacchione; Francesco Bazzini; Marco Calderisi; Giuseppe Buonocore; Mariangela Longini Journal: Cytokine Date: 2018-08-22 Impact factor: 3.861
Authors: Katarina Järlestedt; Catherine I Rousset; Anders Ståhlberg; Hana Sourkova; Alison L Atkins; Claire Thornton; Scott R Barnum; Rick A Wetsel; Mike Dragunow; Milos Pekny; Carina Mallard; Henrik Hagberg; Marcela Pekna Journal: FASEB J Date: 2013-06-04 Impact factor: 5.191
Authors: Anna Stokowska; Alison L Atkins; Javier Morán; Tulen Pekny; Linda Bulmer; Michaela C Pascoe; Scott R Barnum; Rick A Wetsel; Jonas A Nilsson; Mike Dragunow; Marcela Pekna Journal: Brain Date: 2016-12-12 Impact factor: 13.501
Authors: Faith H Brennan; Aileen J Anderson; Stephen M Taylor; Trent M Woodruff; Marc J Ruitenberg Journal: J Neuroinflammation Date: 2012-06-21 Impact factor: 8.322
Authors: Seetha Shankaran; Abbot R Laptook; Athina Pappas; Scott A McDonald; Abhik Das; Jon E Tyson; Brenda B Poindexter; Kurt Schibler; Edward F Bell; Roy J Heyne; Claudia Pedroza; Rebecca Bara; Krisa P Van Meurs; Carolyn M Petrie Huitema; Cathy Grisby; Uday Devaskar; Richard A Ehrenkranz; Heidi M Harmon; Lina F Chalak; Sara B DeMauro; Meena Garg; Michelle E Hartley-McAndrew; Amir M Khan; Michele C Walsh; Namasivayam Ambalavanan; Jane E Brumbaugh; Kristi L Watterberg; Edward G Shepherd; Shannon E G Hamrick; John Barks; C Michael Cotten; Howard W Kilbride; Rosemary D Higgins Journal: JAMA Date: 2017-07-04 Impact factor: 56.272
Authors: Sean M Silverman; Byung-Jin Kim; Garreth R Howell; Joselyn Miller; Simon W M John; Robert J Wordinger; Abbot F Clark Journal: Mol Neurodegener Date: 2016-03-24 Impact factor: 14.195